Table 2. The characteristics of the included studies in meta-analysis.
| CRP (mean±SD.mg/L) | ||||||||||||||
| Study | Year | Country | PCOS Definition | No. | BMI | Age |
Time (months) |
Dose(mg/day) | Method | pre | post | HOMA-IR ratio | T ratio | Score |
| Banaszewska | 2009 | USA | Rotterdam | 36 | <25 | 25.2±0.7 | 3 | 1700 | ECLIA | 2.56±0.64 | 1.23±0.7 | 0.90 | 0.86 | 8 |
| Banaszewska | 2011 | USA | Rotterdam | 47 | <25 | 26.0 ±0.6 | 6 | 1700 | ECLIA | 2.5±0.5 | 1.18±0.7 | 1.05 | 0.82 | 8 |
| Behradmanesh | 2011 | Iran | Homburg | 12 | <25 | 22.5±4.5 | 3 | 1500 | IRMA | 1.4±0.73 | 1.3±0.4 | 0.62 | NR | 9 |
| Behradmanesh | 2011 | Iran | Homburg | 14 | ≥25 | 22.5±4.5 | 3 | 1500 | IRMA | 5.07±5.7 | 2.9±1.9 | 1.21 | NR | 9 |
| Behradmanesh | 2011 | Iran | Homburg | 19 | ≥25 | 22.5±4.5 | 3 | 1500 | IRMA | 2.8±2.4 | 2.5±2.8 | 1.39 | NR | 9 |
| Celik | 2012 | Turkey | Rotterdam | 20 | ≥25 | 25.9±5.7 | 3 | 2000 | ITM | 0.72±0.4 | 0.3±0.2 | 0.84 | 0.91 | 8 |
| Cetinkalp | 2009 | Turkey | Rotterdam | 47 | ≥25 | NR | 4 | 2000 | ITM | 1±1.86 | 0.28±0.3 | 0.86 | 0.85 | 8 |
| Diamanti-Kandarakis | 2006 | Greek | Rotterdam | 22 | ≥25 | 24.3± 0.6 | 6 | 1700 | ELISA | 1.92±0.6 | 0.52±0.3 | 0.67 | 0.89 | 8 |
| Esfahanian | 2013 | Iran | Rotterdam | 17 | ≥25 | 21.9±9.3 | 3 | 2000 | ITM | 5.2±2.5 | 3.7±1.9 | 0.80 | 0.63 | 8 |
| Heutling | 2008 | UK | Rotterdam | 21 | ≥25 | 27.8± 4.7 | 6 | 1700 | ITM | 4±3 | 4±2.2 | 0.84 | 0.70 | 8 |
| Hoeger | 2008 | USA | Rotterdam | 6 | ≥25 | 16± 1.7 | 6 | 2000 | CLIA | 3.6±2.7 | 2.8±2 | 0.88 | 1.04 | 5 |
| Jakubowska | 2008 | Poland | Rotterdam | 29 | ≥25 | 28.2±6.3 | 6 | 1000 | ITM | 3.53±3.64 | 3.73±3.7 | 0.98 | 0.59 | 9 |
| Mohiyiddeen | 2013 | UK | Rotterdam | 17 | ≥25 | 30.0± 0.9 | 3 | 1000 | CLIA | 4.11±1.09 | 1.98±0.6 | 0.66 | 0.83 | 9 |
| Mohlig | 2004 | Germany | NIH | 9 | ≥25 | 28.9±0.7 | 6 | 2550 | ITM | 3.34±0.82 | 1.92±0.3 | 1.20 | 0.71 | 6 |
| Morin-Papunen | 2003 | Finland | Homburg | 8 | <25 | 28.2±1.2 | 3 | 1000 | ITM | 1.34±0.39 | 1.2±0.4 | NR | NR | 5 |
| Morin-Papunen | 2003 | Finland | Homburg | 8 | ≥25 | 29.5±1.1 | 3 | 1000 | ITM | 4.83±1.05 | 2.85±0.9 | NR | NR | 5 |
| Morin-Papunen | 2003 | Finland | Homburg | 8 | <25 | 28.2±1.2 | 6 | *1000-2000 | ITM | 1.34±0.39 | 0.92±0.3 | NR | NR | 5 |
| Morin-Papunen | 2003 | Finland | Homburg | 8 | ≥25 | 29.5±1.1 | 6 | *1000-2000 | ITM | 4.83±1.05 | 2.11±0.4 | NR | NR | 5 |
| Orio | 2007 | Italy | Rotterdam | 50 | ≥25 | 28.5±3.1 | 6 | 1700 | ITM | 1.8±0.9 | 1.1±0.6 | 0.54 | 0.93 | 10 |
| Velija-Ašimi | 2007 | Bosnia and Herzegovina | Rotterdam | 35 | ≥25 | 20-35 | 12 | 850 | ITM | 6.37±1.72 | 1.67±0.7 | NR | 0.72 | 7 |
Abbreviations: CRP, C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; T ratio: total testosterone ratio; CLIA, Chemiluminescent immunoassay; ITM, immunoturbidimetry; IRMA, immunoradiometric assay; ECLIA, electrochemiluminescence immunoassay; ELISA, Enzyme-linked immunosorbent assay; SD, standard deviation; NR, not reported;*1000-2000, 1000mg/day for 3 months, then 2000 mg/day for 3 months. Score, quality score